Brief: Monopar Therapeutics Reports Q1 2023 Financial Results And Recent Developments
11/05/2023 13:49
May 11 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND RECENT DEVELOPMENTS
* MONOPAR THERAPEUTICS INC - NET LOSS FOR Q1 OF 2023 WAS OR
$0.19
PER SHARE
* MONOPAR THERAPEUTICS INC-TO NOT INCUR ANY LICENSE, ROYALTY
OBLIGATIONS & IS NOT ANTICIPATING SIGNIFICANT EXPENSES BEYOND Q2
2023 RELATED TO VALIDIVE
* MONOPAR THERAPEUTICS INC - ESTIMATES CASH, CASH
EQUIVALENTS,
SHORT-TERM INVESTMENTS WILL FUND COMPANY'S PLANNED OPERATIONS AT
LEAST THROUGH JUNE 2024
Source text for Eikon: ID:nGNX1TgJY3
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla